Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Discover high-quality research tools to investigate GLP-1 mechanisms and next-generation metabolic targets.
OBESITY RESEARCH SOLUTIONSVO-OHpic is a specific inhibitor of phosphatase and tensin homolog (PTEN; IC50 = 35 nM in vitro).1,2 Through this action, it increases cellular phosphatidylinositol 3,4,5-trisphosphate (PIP3) levels, phosphorylation of Akt, and glucose uptake in adipocytes.1 In mice, VO-OHpic (10 µg/kg, i.p.) decreases left ventricular systolic pressure and heart rate and protects against ischemia/reperfusion-induced myocardial infarction.3 VO-OHpic also blocks the development of suppressor activity in regulatory T cells activated with indoleamine 2,3-dioxygenase.4
WARNING This product is not for human or veterinary use.
1. A small-
2. Characterisation of the PTEN inhibitor VO-
3. PTEN inhibitors cause a negative inotropic and chronotropic effect in mice. Eur. J. Pharmacol. 650(1), 298-302 (2011).
4. The PTEN pathway in Tregs is a critical driver of the suppressive tumor microenvironment. Sci. Adv. 1(10), e1500845 (2015).